AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (77)

Latest Posts

About This Stock More About This Stock
4 No-Brainer Pharmaceutical Stocks To Buy In October
Article By: StockNews
Monday, September 27, 2021 9:00 PM EDT
While the resurgence of COVID-19 cases is driving the demand for vaccines, booster shots, and other related solutions, an aging population is expected to be a key growth driver for the pharmaceutical industry.
In this article: ALPMY, AZN, GSK, JNJ
5 Best Dividend Stocks To Buy Now
Article By: Money Morning
Thursday, August 26, 2021 11:15 AM EDT
There's no better time than now to invest in dividend stocks. And some of the best dividend stocks that beat the S&P 500's average yield of 2% can be found in the healthcare sector.
In this article: AZN, GSK, JNJ, PFE, ABBV
E Sunday Update - UK Disarray, Brazilian Kisses
Article By: Vivian Lewis
Sunday, August 15, 2021 11:21 AM EDT
News from the UK, China and Brazil, with the latest from Cosan.
In this article: AZN, CZZ, GSK, NIO, SSEZY
3 Big Drugmakers To Buy Ahead Of The Q2 Earnings Season
Article By: Zacks Investment Research
Saturday, July 10, 2021 4:00 AM EDT
The big drug companies are set for the second-quarter earnings season, which begins later this month.
In this article: AZN, BAYRY, ABBV
3 Promising Oncology Stocks To Consider Adding To Your Portfolio
Article By: StockNews
Monday, June 14, 2021 12:31 AM EDT
With tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca, Amgen and Incyte are worth adding to a portfolio.
In this article: AZN, INCY, AMGN Also: SPY, CNCR

Latest Tweets for $AZN

No tweets yet!



Astrazeneca Vs. Novavax: Which Vaccine Stock Is A Better Buy?
Karen Klein 2/14/2021 4:58:18 AM

$AZN looks like the best option since it's easy to transport and so cheap to produce. But it sounds like it's not particularly effective against the new strains.

VistaGen Is Prepared For 2021 Fueled By Recent Analyst Upgrades And Large Institutional Buyers
Terrence Howard 1/11/2021 6:59:49 AM

Good article, thanks. Totally unrelated but what do you think about $AZN? I know Pfizer and Moderna have the head start on the vaccine, but it sounds like AZN's drug will be almost as effective at 90% efficacy (if they can replicate their initial test where they accidentally gave a quarter of the participants a 1/2 dose). And at $2 per vial instead of $200, I would think it will be the drug of choice for populous, yet poor nations like India, and Africa. Plus there will be no need for specialized freezers.

AstraZeneca Vaccine Only 62% Effective; Impact On Elderly Unclear As More Data Needed
Craig Newman 12/8/2020 5:20:20 PM

$AZN has not even filed or talked about filing in US or UK to my knowledge. They are hoping to get India to bite first via Serum Institute. Their trial was so F'd UP the most value to FDA is in denying to prove that other approvals are REAL..

Market Briefing For Thursday, September 10
Adam Reynolds 11/29/2020 5:39:15 PM

What's your take on the latest news on $AZN?

Good Day For Bad News
Ayelet Wolf 11/29/2020 5:37:45 PM

I thought this as well. 90% efficacy is almost as good as the 95% efficacy of the #Pfizer and #Moderna vaccines. But is a much cheaper alternative. Bullish on $AZN

Market Briefing For Thursday, September 10
Atif Ozcelik 9/10/2020 10:37:10 AM

Comments on the major vaccine producers are very useful; thank for the information on $SRNE, $AZN.

When Profits and Politics Drive Science: Rushing a Vaccine to Market for a Vanishing Virus
Adam Reynolds 6/4/2020 5:09:08 PM

Yes and Fauci and other experts said corona is likely here to stay. We will probably have seasonal outbreaks every year. There will be plenty of time to profit from a vaccine. Bullish on $AZN, $MRNA.

1 to 7 of 7 comments